Symbols / LYRA
LYRA Chart
About
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.58M |
| Enterprise Value | 11.91M | Income | -32.95M | Sales | 600.00K |
| Book/sh | -2.63 | Cash/sh | 12.43 | Dividend Yield | — |
| Payout | 0.00% | Employees | 30 | IPO | — |
| P/E | — | Forward P/E | -1.47 | PEG | — |
| P/S | 4.30 | P/B | -0.55 | P/C | — |
| EV/EBITDA | -0.37 | EV/Sales | 19.84 | Quick Ratio | 2.33 |
| Current Ratio | 2.43 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -22.90 | EPS next Y | -0.99 | EPS Growth | — |
| Revenue Growth | -87.20% | Earnings | 2025-11-12 16:00 | ROA | -33.08% |
| ROE | -4.04% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -250.32% | Profit Margin | 0.00% | Shs Outstand | 1.77M |
| Shs Float | 365.70K | Short Float | 3.92% | Short Ratio | 0.45 |
| Short Interest | — | 52W High | 37.50 | 52W Low | 1.21 |
| Beta | -0.06 | Avg Volume | 88.93K | Volume | 19.59K |
| Target Price | $16.00 | Recom | None | Prev Close | $1.45 |
| Price | $1.46 | Change | 0.34% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.00
Mean price target
2. Current target
$1.46
Latest analyst target
3. DCF / Fair value
$-205.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.46
Low
$16.00
High
$16.00
Mean
$16.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-14 | reit | HC Wainwright & Co. | Neutral → Neutral | $16 |
| 2025-06-10 | main | HC Wainwright & Co. | Neutral → Neutral | $16 |
| 2025-03-14 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-08-15 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-08-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-06-20 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-05-07 | down | HC Wainwright & Co. | Buy → Neutral | $2 |
| 2024-05-07 | down | Jefferies | Buy → Hold | $1 |
| 2024-05-06 | down | BTIG | Buy → Neutral | — |
| 2024-05-01 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-03-25 | main | B of A Securities | Buy → Buy | $11 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-10-02 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-09-12 | main | B of A Securities | Buy → Buy | $15 |
| 2023-08-31 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2023-02-07 | main | BTIG | — → Buy | $20 |
| 2022-05-24 | init | Cantor Fitzgerald | — → Overweight | $15 |
| 2020-05-26 | init | B of A Securities | — → Buy | $21 |
| 2020-05-26 | init | Jefferies | — → Buy | $24 |
- (LYRA) Risk Channels and Responsive Allocation - Stock Traders Daily Sat, 21 Feb 2026 06
- Nasdaq plans to delist Lyra Therapeutics (LYRA) after shell status finding - Stock Titan Fri, 06 Feb 2026 08
- Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - Yahoo Finance hu, 05 Jun 2025 07
- Lyra Therapeutics Provides Corporate Update - GlobeNewswire Mon, 12 Jan 2026 08
- Lyra Therapeutics Faces Nasdaq Delisting After Becoming Shell - The Globe and Mail Sat, 07 Feb 2026 08
- BTIG reiterates Neutral rating on Lyra Therapeutics stock after Q3 results - Investing.com hu, 13 Nov 2025 08
- Lyra Therapeutics Shares Soar 603.25% to $34.67 on LYR-210 Trial Success - TradingPedia Mon, 02 Jun 2025 07
- Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate - Stocktwits Mon, 06 Oct 2025 07
- Lyra Therapeutics common stock to be delisted by Nasdaq - TipRanks Fri, 06 Feb 2026 08
- Lyra Therapeutics Announces Clinical Plan for LYR-210 Following Positive ENLIGHTEN 2 Results and Upcoming FDA Engagement | LYRA Stock News - Quiver Quantitative Mon, 06 Oct 2025 07
- Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates - Nasdaq ue, 12 Aug 2025 07
- Lyra Therapeutics First Half 2025 Earnings: In Line With Expectations - simplywall.st Fri, 15 Aug 2025 07
- Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha Mon, 16 Jun 2025 07
- Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire Wed, 12 Nov 2025 08
- Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why - Yahoo Finance hu, 12 Jun 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1702 | 5726.0 | — | Sale at price 3.36 per share. | PALASIS MARIA | Chief Executive Officer | — | 2026-01-06 00:00:00 | D |
| 1 | 769 | 2587.0 | — | Sale at price 3.36 per share. | CAVALIER JASON | Chief Financial Officer | — | 2026-01-06 00:00:00 | D |
| 2 | 45875 | 182515.0 | — | Sale at price 3.90 - 4.31 per share. | PERCEPTIVE ADVISORS LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-13 00:00:00 | I |
| 3 | 70390 | 344219.0 | — | Sale at price 4.54 - 5.18 per share. | PERCEPTIVE ADVISORS LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-10 00:00:00 | I |
| 4 | 1565 | 13944.0 | — | Sale at price 8.91 per share. | PALASIS MARIA | Chief Executive Officer | — | 2025-07-10 00:00:00 | D |
| 5 | 684 | 6094.0 | — | Sale at price 8.91 per share. | CAVALIER JASON | Chief Financial Officer | — | 2025-07-10 00:00:00 | D |
| 6 | 800000 | nan | — | — | PALASIS MARIA | Chief Executive Officer | — | 2025-01-08 00:00:00 | D |
| 7 | 420000 | nan | — | — | CAVALIER JASON | Chief Financial Officer | — | 2025-01-08 00:00:00 | D |
| 8 | 300000 | nan | — | — | PALASIS MARIA | Chief Executive Officer | — | 2024-10-16 00:00:00 | D |
| 9 | 100000 | nan | — | — | CAVALIER JASON | Chief Financial Officer | — | 2024-10-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -276.36K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.00 |
| NormalizedEBITDA | -24.65M | -63.66M | -52.61M | -42.61M |
| TotalUnusualItems | -35.62M | -1.59M | -1.32M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -35.62M | -1.59M | -1.32M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -93.44M | -62.68M | -55.28M | -43.51M |
| ReconciledDepreciation | 471.00K | 278.00K | 1.07M | 1.00M |
| EBITDA | -60.26M | -65.25M | -53.92M | -42.61M |
| EBIT | -60.73M | -65.53M | -54.99M | -43.62M |
| NetInterestIncome | 2.95M | 4.50M | 1.04M | 102.00K |
| InterestIncome | 2.95M | 4.50M | 1.04M | 102.00K |
| NormalizedIncome | -57.82M | -61.09M | -54.24M | -43.51M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -93.44M | -62.68M | -55.28M | -43.51M |
| TotalExpenses | 62.27M | 67.09M | 56.35M | 43.90M |
| TotalOperatingIncomeAsReported | -96.35M | -67.12M | -56.31M | -43.62M |
| DilutedAverageShares | 1.30M | 996.09K | 604.71K | 259.72K |
| BasicAverageShares | 1.30M | 996.09K | 604.71K | 259.72K |
| DilutedEPS | -71.50 | -63.00 | -91.50 | -167.50 |
| BasicEPS | -71.50 | -63.00 | -91.50 | -167.50 |
| DilutedNIAvailtoComStockholders | -93.44M | -62.68M | -55.28M | -43.51M |
| NetIncomeCommonStockholders | -93.44M | -62.68M | -55.28M | -43.51M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -93.44M | -62.68M | -55.28M | -43.51M |
| NetIncomeIncludingNoncontrollingInterests | -93.44M | -62.68M | -55.28M | -43.51M |
| NetIncomeContinuousOperations | -93.44M | -62.68M | -55.28M | -43.51M |
| TaxProvision | 39.00K | 59.00K | 13.00K | 0.00 |
| PretaxIncome | -93.40M | -62.62M | -55.27M | -43.51M |
| OtherIncomeExpense | -35.62M | -1.59M | -1.32M | |
| SpecialIncomeCharges | -35.62M | -1.59M | -1.32M | 0.00 |
| ImpairmentOfCapitalAssets | 24.72M | 1.59M | 1.32M | 0.00 |
| RestructuringAndMergernAcquisition | 10.90M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 2.95M | 4.50M | 1.04M | 102.00K |
| InterestIncomeNonOperating | 2.95M | 4.50M | 1.04M | 102.00K |
| OperatingIncome | -60.73M | -65.53M | -54.99M | -43.62M |
| OperatingExpense | 62.27M | 67.09M | 56.35M | 43.90M |
| ResearchAndDevelopment | 43.77M | 48.03M | 38.80M | 29.69M |
| SellingGeneralAndAdministration | 18.50M | 19.06M | 17.56M | 14.21M |
| GeneralAndAdministrativeExpense | 18.50M | 19.06M | 17.56M | 14.21M |
| OtherGandA | 18.50M | 19.06M | 17.56M | 14.21M |
| TotalRevenue | 1.53M | 1.56M | 1.36M | 285.00K |
| OperatingRevenue | 1.53M | 1.56M | 1.36M | 285.00K |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.31M | 1.14M | 636.55K | 260.14K |
| ShareIssued | 1.31M | 1.14M | 636.55K | 260.14K |
| TotalDebt | 34.38M | 26.88M | 4.18M | 1.45M |
| TangibleBookValue | 11.59M | 89.42M | 80.75M | 34.32M |
| InvestedCapital | 11.59M | 89.42M | 80.75M | 34.32M |
| WorkingCapital | 30.39M | 85.22M | 86.36M | 29.67M |
| NetTangibleAssets | 11.59M | 89.42M | 80.75M | 34.32M |
| CapitalLeaseObligations | 34.38M | 26.88M | 4.18M | 1.45M |
| CommonStockEquity | 11.59M | 89.42M | 80.75M | 34.32M |
| TotalCapitalization | 11.59M | 89.42M | 80.75M | 34.32M |
| TotalEquityGrossMinorityInterest | 11.59M | 89.42M | 80.75M | 34.32M |
| StockholdersEquity | 11.59M | 89.42M | 80.75M | 34.32M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 33.00K | 10.00K | 0.00 |
| OtherEquityAdjustments | 33.00K | 10.00K | ||
| RetainedEarnings | -404.79M | -311.36M | -248.68M | -193.40M |
| AdditionalPaidInCapital | 416.32M | 400.69M | 329.39M | 227.70M |
| CapitalStock | 65.00K | 57.00K | 32.00K | 13.00K |
| CommonStock | 65.00K | 57.00K | 32.00K | 13.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 54.75M | 53.18M | 29.21M | 20.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 42.12M | 33.58M | 14.74M | 2.31M |
| NonCurrentDeferredLiabilities | 11.86M | 12.14M | 14.08M | 1.93M |
| NonCurrentDeferredRevenue | 11.86M | 12.14M | 14.08M | 1.93M |
| LongTermDebtAndCapitalLeaseObligation | 30.26M | 21.45M | 667.00K | 379.00K |
| LongTermCapitalLeaseObligation | 30.26M | 21.45M | 667.00K | 379.00K |
| CurrentLiabilities | 12.63M | 19.60M | 14.47M | 18.25M |
| OtherCurrentLiabilities | 4.82M | 1.23M | 659.00K | 633.00K |
| CurrentDeferredLiabilities | 398.00K | 1.66M | 1.27M | 9.79M |
| CurrentDeferredRevenue | 398.00K | 1.66M | 1.27M | 9.79M |
| CurrentDebtAndCapitalLeaseObligation | 4.12M | 5.43M | 3.51M | 1.07M |
| CurrentCapitalLeaseObligation | 4.12M | 5.43M | 3.51M | 1.07M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.43M | |||
| PayablesAndAccruedExpenses | 3.29M | 11.27M | 9.03M | 6.75M |
| CurrentAccruedExpenses | 2.11M | 8.14M | 6.41M | 3.62M |
| Payables | 1.18M | 3.13M | 2.62M | 3.12M |
| AccountsPayable | 1.18M | 3.13M | 2.62M | 3.12M |
| TotalAssets | 66.35M | 142.60M | 109.97M | 54.87M |
| TotalNonCurrentAssets | 23.32M | 37.78M | 9.14M | 6.95M |
| OtherNonCurrentAssets | 1.99M | 2.50M | 4.67M | 1.09M |
| NetPPE | 21.33M | 35.28M | 4.47M | 5.86M |
| AccumulatedDepreciation | -4.13M | -1.92M | -4.17M | -3.88M |
| GrossPPE | 25.46M | 37.20M | 8.64M | 9.74M |
| Leases | 486.00K | 461.00K | 397.00K | 2.11M |
| ConstructionInProgress | 0.00 | |||
| OtherProperties | 23.85M | 35.97M | 7.25M | 6.65M |
| MachineryFurnitureEquipment | 1.12M | 767.00K | 998.00K | 976.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 43.02M | 104.82M | 100.83M | 47.92M |
| OtherCurrentAssets | 2.45M | 2.07M | 2.94M | 2.17M |
| PrepaidAssets | 2.17M | |||
| CashCashEquivalentsAndShortTermInvestments | 40.58M | 102.75M | 97.89M | 45.75M |
| OtherShortTermInvestments | 0.00 | 80.40M | 65.34M | 0.00 |
| CashAndCashEquivalents | 40.58M | 22.35M | 32.55M | 45.75M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -72.35M | -64.35M | -43.55M | -29.20M |
| IssuanceOfCapitalStock | 8.82M | 69.24M | 100.50M | 0.00 |
| CapitalExpenditure | -2.34M | -1.05M | -164.00K | -3.38M |
| EndCashPosition | 42.57M | 23.75M | 33.94M | 46.08M |
| BeginningCashPosition | 23.75M | 33.94M | 46.08M | 74.92M |
| ChangesInCash | 18.82M | -10.20M | -12.13M | -28.85M |
| FinancingCashFlow | 8.53M | 65.69M | 96.26M | 359.00K |
| CashFlowFromContinuingFinancingActivities | 8.53M | 65.69M | 96.26M | 359.00K |
| NetOtherFinancingCharges | -290.00K | -3.65M | -4.25M | -245.00K |
| ProceedsFromStockOptionExercised | 3.00K | 103.00K | 8.00K | 604.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 8.82M | 69.24M | 100.50M | 0.00 |
| CommonStockIssuance | 8.82M | 69.24M | 100.50M | 0.00 |
| InvestingCashFlow | 80.31M | -12.58M | -65.01M | -3.38M |
| CashFlowFromContinuingInvestingActivities | 80.31M | -12.58M | -65.01M | -3.38M |
| NetInvestmentPurchaseAndSale | 82.64M | -11.54M | -64.84M | 0.00 |
| SaleOfInvestment | 130.59M | 110.89M | 0.00 | |
| PurchaseOfInvestment | -47.95M | -122.42M | -64.84M | 0.00 |
| NetPPEPurchaseAndSale | -2.34M | -1.05M | -164.00K | -3.38M |
| PurchaseOfPPE | -2.34M | -1.05M | -164.00K | -3.38M |
| OperatingCashFlow | -70.01M | -63.30M | -43.38M | -25.82M |
| CashFlowFromContinuingOperatingActivities | -70.01M | -63.30M | -43.38M | -25.82M |
| ChangeInWorkingCapital | -6.35M | -4.88M | 4.55M | 13.92M |
| ChangeInOtherWorkingCapital | -1.53M | -1.56M | 3.64M | 11.71M |
| ChangeInOtherCurrentLiabilities | 966.00K | -1.21M | 763.00K | -986.00K |
| ChangeInOtherCurrentAssets | 2.46M | -4.93M | -1.44M | 446.00K |
| ChangeInPayablesAndAccruedExpense | -7.86M | 1.94M | 2.36M | 3.59M |
| ChangeInAccruedExpense | -5.97M | 1.49M | 4.77M | 1.24M |
| ChangeInPayable | -1.89M | 450.00K | -2.41M | 2.35M |
| ChangeInAccountPayable | -1.89M | 450.00K | -2.41M | 2.35M |
| ChangeInPrepaidAssets | -380.00K | 867.00K | -764.00K | -847.00K |
| StockBasedCompensation | 6.72M | 5.89M | 5.45M | 2.77M |
| AssetImpairmentCharge | 24.86M | 1.59M | 1.32M | 0.00 |
| AmortizationOfSecurities | -2.28M | -3.50M | -492.00K | 0.00 |
| DepreciationAmortizationDepletion | 471.00K | 278.00K | 1.07M | 1.00M |
| DepreciationAndAmortization | 471.00K | 278.00K | 1.07M | 1.00M |
| Depreciation | 471.00K | 278.00K | 1.07M | 1.00M |
| NetIncomeFromContinuingOperations | -93.44M | -62.68M | -55.28M | -43.51M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LYRA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|